Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years.
about
Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine TrialsDocumenting the Results of a Successful Partnership: A New Meningococcal Vaccine for Africa.Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age.Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix™): A review of its immunogenicity, safety, co-administration, and antibody persistence.Proceedings of the first African Health Forum: effective partnerships and intersectoral collaborations are critical for attainment of Universal Health Coverage in Africa
P2860
Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Antibody Persistence at 1 and ...... lthy Subjects Aged 2-29 Years.
@ast
Antibody Persistence at 1 and ...... lthy Subjects Aged 2-29 Years.
@en
type
label
Antibody Persistence at 1 and ...... lthy Subjects Aged 2-29 Years.
@ast
Antibody Persistence at 1 and ...... lthy Subjects Aged 2-29 Years.
@en
prefLabel
Antibody Persistence at 1 and ...... lthy Subjects Aged 2-29 Years.
@ast
Antibody Persistence at 1 and ...... lthy Subjects Aged 2-29 Years.
@en
P2093
P2860
P50
P356
P1476
Antibody Persistence at 1 and ...... lthy Subjects Aged 2-29 Years.
@en
P2093
Adebayo K Akinsola
Aldiouma Diallo
Ashish Bavdekar
Bou Diarra
Brian D Plikaytis
Cheryl Elie
Elisa Marchetti
Fadima Cheick Haidara
Fatoumata Diallo
George Carlone
P2860
P304
P356
10.1093/CID/CIV518
P407
P478
61 Suppl 5
P577
2015-11-01T00:00:00Z